日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Minnesota Critical Care Working Group 1: Monitoring and Coordinating Statewide Critical Care Surge Response in the COVID-19 Pandemic, March 2020 Through July 1, 2021

明尼苏达州重症监护工作组 1:监测和协调 COVID-19 大流行期间全州重症监护激增应对措施,2020 年 3 月至 2021 年 7 月 1 日

Dichter, Jeffrey R; Brown, Daniel; Zamorano, Clara; Cohen, Joshua; Miller, Elizabeth A; Niccum, David E; LeClaire, Michele; De Jong, Christina Bastin; Diebold, Deanna; Lyons, Jacob; Reilkoff, Ronald; Erickson, Heidi L; Martinelli, Joseph; Fischer, Jennifer A; Mairose, Kyle; Kallestad, Jason; Chell, Christine; Shadiow, Adam; Stoen, Shawn; Hick, John L; Petersen-Kroeber, Cheryl; Seaberg, Judy; McLachlan, Erin; Waterman, Alexandra T; James, Walter Y; MacDonell, Sean; Risser, James; Klemond, Tom; DeMartino, Erin S; Wu, Joel; DeBruin, Debra; Wolf, Susan M; Sederstrom, Nneka O; Baum, Karyn D; Greenlee, Kay; Strike, Helen; Kettler, Paul A; Boehland, Andrea; Goodman, Kimberly A; Maslonka, Ken K; Wolf, Jack M; Schoenecker, Jennifer; Kesler, Sarah M

The Minnesota Critical Care Working Group 2: Crisis Conditions During the COVID-19 Pandemic, July 2021 through March 2022

明尼苏达州重症监护工作组 2:COVID-19 大流行期间的危机状况,2021 年 7 月至 2022 年 3 月

Kesler, Sarah M; De Jong, Christina Bastin; Chell, Christine; DeBruin, Debra; Erickson, Heidi L; Goodman, Kimberly A; James, Walter Y; Kallestad, Jason; Klemond, Tom; McLachlan, Erin; Petersen-Kroeber, Cheryl; Risser, James; DeMartino, Erin S; Waterman, Alexandra T; Wolf, Susan M; Wu, Joel; Zamorano, Clara; Baum, Karyn D; Brown, Daniel; Cohen, Joshua; Diebold, Deanna; Fischer, Jennifer A; Greenlee, Kay; Hick, John L; Kettler, Paul A; LeClaire, Michele; Lyons, Jacob; MacDonell, Sean; Mairose, Kyle; Boehland, Andrea; Martinelli, Joseph; Miller, Elizabeth A; Niccum, David E; Reilkoff, Ronald; Seaberg, Judy; Sederstrom, Nneka O; Shadiow, Adam; Stoen, Shawn; Strike, Helen; Maslonka, Ken K; Wolf, Jack M; Schoenecker, Jennifer; Dichter, Jeffrey R

Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status

一项随机 II 期试验,评估帕博利珠单抗单药治疗或联合低剂量化疗治疗非小细胞肺癌且体能状态较差的患者的疗效。

Addo, Safoa; Lycan, Thomas; Soto-Pantoja, David R; Tsai, Yu-Ting; Stoen, Ericson; Ahmed, Tamjeed; Evans, Joni K; Hart, Lowell; Ruiz, Jimmy; Triozzi, Pierre; Bonomi, Marcelo; Petty, W Jeffrey

High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients

肿瘤上皮中 miR-17-5p 高表达是前列腺癌患者预后不良的预测因素

Maria Jenvin Stoen, S Andersen, M Rakaee, M I Pedersen, L M Ingebriktsen, R M Bremnes, T Donnem, A P G Lombardi, T K Kilvaer, L T Busund, E Richardsen

Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval

来自大学医院系统的真实世界证据,反映了帕妥珠单抗和/或奈拉替尼在获得FDA批准前后辅助治疗的接受情况。

Stoen, Ericson; Kagihara, Jodi; Shagisultanova, Elena; Fisher, Christine M; Nicklawsky, Andrew; Kabos, Peter; Borges, Virginia F; Diamond, Jennifer R

Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer-A Multi-Institutional Study

miR-20a-5p 在肿瘤上皮中的过度表达是前列腺癌的独立负面预后指标——一项多机构研究

Maria J Stoen, Sigve Andersen, Mehrdad Rakaee, Mona I Pedersen, Lise M Ingebriktsen, Tom Donnem, Ana P G Lombardi, Thomas K Kilvaer, Lill-Tove R Busund, Elin Richardsen